[HTML][HTML] Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non …
Y Xu, J Yan, C Zhou, L Wu, H Wang, J Zhao… - European Journal of …, 2023 - Elsevier
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
receptor (EGFR) mutation generally respond well to epidermal growth factor receptor …
[HTML][HTML] Concomitant genetic alterations are associated with worse clinical outcome in EGFR mutant NSCLC patients treated with tyrosine kinase inhibitors
SC Chang, YC Lai, CY Chang, LK Huang, SJ Chen… - Translational …, 2019 - Elsevier
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are recommended
first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR …
first-line therapy for advanced non-small cell lung cancer (NSCLC) with sensitizing EGFR …
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
M Kanazu, M Mori, M Kimura, K Nishino… - Thoracic …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
[HTML][HTML] Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non–small-cell Lung Cancer
Y Zhu, X Qu, D Zhan, H Chen, H Li, L Liu, X Chen… - Clinical Lung Cancer, 2021 - Elsevier
Background There occurs huge heterogeneity in clinical outcomes for epidermal growth
factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients treated with …
factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients treated with …
[HTML][HTML] Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review
Y Guo, J Song, Y Wang, L Huang, L Sun, J Zhao… - Frontiers in …, 2020 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
Influence of concurrent mutations on overall survival in EGFR-mutated non-small cell lung cancer
M Chevallier, P Tsantoulis, A Addeo… - Cancer genomics & …, 2020 - cgp.iiarjournals.org
Background/Aim: Non-small cell lung cancer (NSCLC) patients with activating somatic
mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine …
mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine …
[HTML][HTML] High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
F Wang, S Fu, Q Shao, YB Zhou, X Zhang… - Journal of translational …, 2013 - Springer
Background This study was designed to determine whether advanced non-small-cell lung
cancer (NSCLC) patients with high copy number of epidermal growth factor receptor (EGFR) …
cancer (NSCLC) patients with high copy number of epidermal growth factor receptor (EGFR) …
Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and Exon 19 deletion lung cancer
JA Hellyer, MN White, RM Gardner, K Cunanan… - Clinical Lung Cancer, 2022 - Elsevier
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors
Y Cheng, L Ma, Y Liu, J Zhu, Y Xin, X Liu, Y Wang… - Lung cancer, 2020 - Elsevier
Objectives Although the majority of epidermal growth factor receptor (EGFR)-mutant non-
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …
small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs) …
Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations
A Passaro, A Prelaj, L Bonanno, M Tiseo, A Tuzi… - Clinical lung cancer, 2019 - Elsevier
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …
predictive and druggable mutations that greatly modified patient prognoses. The most …